VEGF/DLL4 binding agents and uses thereof

1. An isolated bispecific antibody that specifically binds human VEGF and human DLL4, comprising a heavy chain of SEQ ID NO:7, a heavy chain of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:56, or SEQ ID NO:62, and two light chains of SEQ ID NO:8.

2. An isolated bispecific antibody selected from the group consisting of 219R45-MB-21M18, 219R45-MB-21R79, 219R45-MB-21R75, and 219R45-MB-21R83.

3. An isolated bispecific antibody comprising:

a) a first antigen-binding site that specifically binds human VEGF, and

b) a second antigen-binding site that specifically binds human DLL4, wherein the first antigen-binding site comprises a heavy chain CDR1 comprising NYWMH (SEQ ID NO:17), a heavy chain CDR2 comprising DINPSNGRTSYKEKFKR (SEQ ID NO:18), and a heavy chain CDR3 comprising HYDDKYYPLMDY (SEQ ID NO:19);

wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13) or AYYIH (SEQ ID NO:79), a heavy chain CDR2 comprising YIANYNRATNYNQKFKG (SEQ ID NO:14), YISSYNGATNYNQKFKG (SEQ ID NO:15), YIAGYKDATNYNQKFKG (SEQ ID NO:59), or YISNYNRATNYNQKFKG (SEQ ID NO:65), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16); and

wherein both the first and second antigen-binding sites comprise a light chain CDR1 comprising RASESVDNYGISFMK (SEQ ID NO:20), a light chain CDR2 comprising AASNQGS (SEQ ID NO:21), and a light chain CDR3 comprising QQSKEVPWTFGG (SEQ ID NO:22).

4. The bispecific antibody of claim 3 wherein

(a) the first antigen-binding site comprises a first heavy chain variable region having at least 90% sequence identity to SEQ ID NO:11;

(b) the second antigen-binding site comprises a second heavy chain variable region having at least 90% sequence identity to SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:58, or SEQ ID NO:64; and

(c) the first and second antigen-binding site comprises a light chain variable region having at least 90% sequence identity to SEQ ID NO:12.

5. The bispecific antibody of claim 3 , which comprises a first CH3 domain and a second CH3 domain, each of which is modified to promote formation of heteromultimers.

6. The bispecific antibody of claim 3 , wherein the first and second CH3 domains are modified based upon electrostatic effects.

7. The bispecific antibody of claim 3 , wherein the first and second CH3 domains are modified using a knobs-into-holes technique.

8. The bispecific antibody of claim 3 , which comprises a first human IgG2 constant region with amino acid substitutions at positions corresponding to positions 249 and 288 of SEQ ID NO:42, wherein the amino acids are replaced with glutamate or aspartate, and a second human IgG2 constant region with amino acid substitutions at positions corresponding to positions 236 and 278 of SEQ ID NO:42, wherein the amino acids are replaced with lysine.

9. The bispecific antibody of claim 3 , which:

(i) inhibits binding of VEGF to at least one VEGF receptor;

(ii) inhibits binding of DLL4 to at least one Notch receptor;

(iii) inhibits Notch signaling; and/or

(iv) modulates angiogenesis.

10. A pharmaceutical composition comprising the bispecific antibody of claim 3 and a pharmaceutically acceptable carrier.

11. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising YIANYNRATNYNQKFKG (SEQ ID NO:14), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).

12. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising YISSYNGATNYNQKFKG (SEQ ID NO:15), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).

13. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising YIAGYKDATNYNQKFKG (SEQ ID NO:59), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).

14. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain CDR1 comprising TAYYIH (SEQ ID NO:13), a heavy chain CDR2 comprising YISNYNRATNYNQKFKG (SEQ ID NO:65), and a heavy chain CDR3 comprising RDYDYDVGMDY (SEQ ID NO:16).

15. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain variable region comprising SEQ ID NO:9.

16. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain variable region comprising SEQ ID NO:10.

17. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain variable region comprising SEQ ID NO:58.

18. The bispecific antibody of claim 3 , wherein the second antigen-binding site comprises a heavy chain variable region comprising SEQ ID NO:64.

19. The bispecific antibody of claim 3 , which is an humanized antibody.

20. The bispecific antibody of claim 3 , which is an IgG1 or IgG2 antibody.

21. A method of inhibiting growth of a tumor in a subject, comprising administering to the subject a therapeutically effective amount of the bispecific antibody of claim 3 .

22. The method of claim 21 , wherein the tumor is selected from the group consisting of colorectal tumor, colon tumor, ovarian tumor, pancreatic tumor, lung tumor, liver tumor, breast tumor, kidney tumor, prostate tumor, gastrointestinal tumor, melanoma, cervical tumor, bladder tumor, glioblastoma, and head and neck tumor.

23. The method of claim 21 , which further comprises administering a second therapeutic agent.

24. A method of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of the bispecific antibody of claim 3 .

25. The method of claim 24 , wherein the cancer is selected from the group consisting of colorectal cancer, colon cancer, ovarian cancer, pancreatic cancer, lung cancer, liver cancer, breast cancer, kidney cancer, prostate cancer, gastrointestinal cancer, melanoma, cervical cancer, bladder cancer, glioblastoma, head and neck cancer, lymphoma and leukemia.